— Why it moved
Why ENSC Stock Spiked and Faded Today — August 6, 2026
Ensysce Biosciences announced a biotech acquisition alongside massive equity dilution, sparking a volume-heavy premarket pop that got crushed by afternoon sellers.
What moved ENSC stock
Ensysce Biosciences is a micro-cap clinical-stage biotech working on relief therapies for severe pain. They put out news before the session's start about acquiring Cy Biopharma while raising funds via private placement preferred stock. Dig into the fine print and existing shareholders just got diluted down to a seven percent stake in the combined entity.
The mechanics
With a float under fifteen million shares, a fifty-nine percent morning gap brought in nearly five hundred million shares of trading volume. That huge turnover wasn't accumulation; it was paper changing hands as fast as traders could flip it before the dilution reality took hold.
ENSC by the numbers
The alert window
The alert hit at 8:17 AM at 0.8449. Anyone jumping in there had to stomach a brutal thirty-seven percent drop almost immediately before the stock crawled up to 0.979 at 9:49 AM. That sixteen percent peak gain was a trap unless you enjoyed holding a falling knife through the session's start.
How ENSC's move ended
By the close, ENSC was sitting at 0.5229, down thirty-eight percent from our alert price. Massive share dilution and structural preferred stock issuances mean this pop was just another liquidity exit for existing debt and dealmakers.
The tell: When a penny biotech acquires a private firm and dilutes existing holders down to single-digit ownership, morning gaps are built for shorting, not holding.